TY - JOUR AU - Rashid, Sadaf AU - Hussain, Zaib AU - Imam, Haider AU - Waris, Abbas Ali AU - Ibrahim, Zahid AU - Farooq, Muhammad AU - Kareem, Owais AU - Umar, Hafiz AU - Saleem, Arslan AU - Zia, Sobia PY - 2013/05/30 Y2 - 2024/03/28 TI - Efficacy and Tolerabilityof Leviteracetum and Topiramate in Patients with Epilepsy JF - Annals of King Edward Medical University JA - Annals KEMU VL - 18 IS - 2 SE - Articles DO - 10.21649/akemu.v18i2.391 UR - https://annalskemu.org/journal/index.php/annals/article/view/391 SP - 143 AB - <span style="font-size: 11pt; font-family: 'Times New Roman', serif;">A total of 50 patients were enrolled for study purpose. The study conducted was a prospective, observational&nbsp;</span><span style="text-align: justify; font-size: 11pt;">study </span><span style="text-align: justify; font-size: 11pt;" lang="EN">from July 2009 to October 2009. </span><span style="text-align: justify; font-size: 11pt;">Patients were seen on five separate occasions (1) Baseline (week 0) At the beginning of initial treatment, patients were divided into two groups i.e; Topiramate gp; and Leve-tiracetam. Patients were given the respective drugs and then asked to follow up after fifteen days. First follow-up visit was after 15 days of treatment, second follow-up visit (30 days after first follow-up visit, third fol-low-up (after 45 days) and final visit (60 days after ini-tial treatment). Levetiracetam was administered at a dose of 250 &ndash; 500 mg b. i. d and Topiramate 50 mg</span><p class="MsoNormal" style="margin-bottom: 6.0pt; text-align: justify; tab-stops: 18.0pt;"><span style="font-size: 11pt;"> b i d. During each phase concomitant anti-epileptic regimes remained constant. In addition Folic acid was prescribed to every patient. Statistical analysis was performed using software SPSS version v. 16.0 for Windows. In the primary analysis 95% confidence intervals for both upper and lower bound means, ANOVA and t-test were performed.</span></p> <p class="MsoNormal" style="margin-bottom: 2.0pt; text-align: justify; tab-stops: 18.0pt;"><strong><span style="font-size: 11pt;">Conclusion:&nbsp;&nbsp;</span></strong><span style="font-size: 11pt;">This study supports the effectiveness of Anti-Epileptic Drugs as add &ndash; on therapy. Topiramate did not prove superior, but it may be a good choice for patients allergic to other anti-epileptic drugs because of the lower risk for rash. Levetiracetam is a broad-spectrum AED and compares well with long &ndash; acting VPA and CBZ. Results may have been better with an Extended Release (ER) formulation of Levetiracetam. The retention rate for LEV is statistically significant as is TPM. LEV had a more favorable side effect profile than TPM with comparable efficacy. Patients on TPM discontinued treatment mainly because of neurocogni-tive side effects and allergic reactions. In the treatment with LEV, the effects on mood must not be underesti-mated.</span></p> <p class="MsoNormal" style="text-align: justify; tab-stops: 18.0pt;"><strong><span style="font-size: 11pt;">Keywords:&nbsp;&nbsp;</span></strong><span style="font-size: 11pt;">Epilepsy, seizures, antiepileptic drugs, levetiracetam, topiramate.</span></p> ER -